Detalhe da pesquisa
1.
Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.
Cell
; 176(4): 775-789.e18, 2019 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30595452
2.
Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.
Cell
; 181(3): 747, 2020 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32359441
3.
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
N Engl J Med
; 387(23): 2113-2125, 2022 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477031
4.
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis.
Lancet Oncol
; 25(4): 509-517, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547894
5.
Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT-confirmed complete response.
Cancer
; 130(3): 433-438, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37788133
6.
Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.
Ann Surg Oncol
; 31(3): 1857-1864, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37966706
7.
Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma.
Ann Surg Oncol
; 30(8): 5017-5026, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36991168
8.
Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
Ann Surg Oncol
; 30(1): 573-586, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36203067
9.
Baseline ultrasound and FDG-PET/CT imaging in Merkel cell carcinoma.
J Surg Oncol
; 127(5): 841-847, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36573839
10.
External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort.
Ann Surg Oncol
; 29(3): 1637-1644, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34816368
11.
Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration.
Ann Surg Oncol
; 29(11): 7010-7017, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35676603
12.
Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience.
Ann Surg Oncol
; 29(2): 791-801, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34648098
13.
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).
Ann Surg Oncol
; 29(6): 3694-3708, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35089452
14.
Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
BMC Cancer
; 22(1): 851, 2022 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35927710
15.
Merkel Cell Carcinoma, the Impact of Clinical Excision Margins and Mohs Micrographic Surgery on Recurrence and Survival: A Systematic Review.
Dermatol Surg
; 48(4): 387-394, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35165221
16.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 643-654, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857412
17.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 655-664, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857414
18.
Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial.
Ann Surg
; 274(2): 383-389, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843797
19.
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
N Engl J Med
; 378(19): 1789-1801, 2018 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658430
20.
T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.
Cancer Immunol Immunother
; 70(8): 2291-2300, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33507342